FDA Approves Two Separate Indications for fam-Trastuzumab Deruxtecan-nxki in HER2-Positive Early-Stage Breast Cancer By Ogkologos - June 17, 2026 59 0 Facebook Twitter Google+ Pinterest WhatsApp FDA also approved two companion diagnostics for identifying patients for treatment with fam-trastuzumab deruxtecan-nxki Source RELATED ARTICLESMORE FROM AUTHOR Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers Editor-in-Chief Opportunities for New ESMO Journals Launching in 2026 Blood Test May Help Identify Which Colorectal Cancer Patients with Liver Metastases Are Most Likely to Benefit from Chemotherapy After Surgery MOST POPULAR Group of Breast Cancer Survivors is Finding New Strength from Fitness... May 11, 2021 Newly Discovered ‘Don’t Eat Me’ Signal May be a Target for... August 20, 2019 People with Intellectual Disability at Increased Risk of Cancer September 21, 2021 FDA Approves Nivolumab for Adjuvant Treatment of Stage IIB/C Melanoma October 26, 2023 Load more HOT NEWS Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer... Can’t Sleep? Tips for Coping with Insomnia Electronic Symptom Monitoring with PROs Improves Patient-Reported Physical Function, Symptom Control,... How to Support a Spouse or Partner During Cancer Treatment by...
